Sepsis pp 213-224 | Cite as

Host Response Biomarkers in Sepsis: The Role of Procalcitonin

  • Jean-Louis VincentEmail author
  • Marc Van Nuffelen
  • Christophe Lelubre
Part of the Methods in Molecular Biology book series (MIMB, volume 1237)


Procalcitonin is the prohormone of calcitonin and present in minute quantities in health. However, during infection, its levels rise considerably and are correlated with the severity of the infection. Several assays have been developed for measurement of procalcitonin levels; in this article, we will briefly present the PCT-sensitive Kryptor® test (Brahms, Hennigsdorf, Germany), one of the most widely used assays for procalcitonin in recent studies. Many studies have demonstrated the value of procalcitonin levels for diagnosing sepsis and assessing disease severity. Procalcitonin levels have also been successfully used to guide antibiotic administration. However, procalcitonin is not specific for sepsis, and values need to be interpreted in the context of a full clinical examination and the presence of other signs and symptoms of sepsis.

Key words

Procalcitonin Prohormone Diagnostic and prognostic marker 


  1. 1.
    Gaieski DF, Mikkelsen ME, Band RA et al (2010) Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 38:1045–1053PubMedCrossRefGoogle Scholar
  2. 2.
    Pierrakos C, Vincent JL (2010) Sepsis biomarkers: a review. Crit Care 14:R15PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Vincent JL (2000) Procalcitonin: THE marker of sepsis? Crit Care Med 28:1226–1228PubMedCrossRefGoogle Scholar
  4. 4.
    Chesney RW, McCarron DM, Haddad JG et al (1983) Pathogenic mechanisms of the hypocalcemia of the staphylococcal toxic-shock syndrome. J Lab Clin Med 101:576–585PubMedGoogle Scholar
  5. 5.
    Becker KL, Nylen ES, White JC et al (2004) Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis—a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 89:1512–1525PubMedCrossRefGoogle Scholar
  6. 6.
    Assicot M, Gendrel D, Carsin H et al (1993) High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341: 515–518PubMedCrossRefGoogle Scholar
  7. 7.
    Muller B, White JC, Nylen ES et al (2001) Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 86:396–404PubMedGoogle Scholar
  8. 8.
    Linscheid P, Seboek D, Nylen ES et al (2003) In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology 144:5578–5584PubMedCrossRefGoogle Scholar
  9. 9.
    Dandona P, Nix D, Wilson MF et al (1994) Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 79:1605–1608PubMedGoogle Scholar
  10. 10.
    Gendrel D, Raymond J, Coste J et al (1999) Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. Pediatr Infect Dis J 18:875–881PubMedCrossRefGoogle Scholar
  11. 11.
    Gilbert DN (2010) Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol 48:2325–2329PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Schuetz P, Albrich WC, Mueller B (2011) Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med 9:107PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Liappis AP, Gibbs KW, Nylen ES et al (2011) Exogenous procalcitonin evokes a pro-inflammatory cytokine response. Inflamm Res 60:203–207PubMedCrossRefGoogle Scholar
  14. 14.
    Hoffmann G, Czechowski M, Schloesser M, Schobersberger W (2002) Procalcitonin amplifies inducible nitric oxide synthase gene expression and nitric oxide production in vascular smooth muscle cells. Crit Care Med 30: 2091–2095PubMedCrossRefGoogle Scholar
  15. 15.
    Nylen ES, Whang KT, Snider RH Jr et al (1998) Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 26:1001–1006PubMedCrossRefGoogle Scholar
  16. 16.
    Martinez JM, Wagner KE, Snider RH et al (2001) Late immunoneutralization of procalcitonin arrests the progression of lethal porcine sepsis. Surg Infect (Larchmt) 2:193–202CrossRefGoogle Scholar
  17. 17.
    Wagner KE, Martinez JM, Vath SD et al (2002) Early immunoneutralization of calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs. Crit Care Med 30: 2313–2321PubMedCrossRefGoogle Scholar
  18. 18.
    Monneret G, Pachot A, Laroche B et al (2000) Procalcitonin and calcitonin gene-related peptide decrease LPS-induced tnf production by human circulating blood cells. Cytokine 12: 762–764PubMedCrossRefGoogle Scholar
  19. 19.
    Matera G, Quirino A, Giancotti A et al (2012) Procalcitonin neutralizes bacterial LPS and reduces LPS-induced cytokine release in human peripheral blood mononuclear cells. BMC Microbiol 12:68PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
  21. 21.
    Jin M, Khan AI (2010) Procalcitonin: uses in the clinical laboratory for the diagnosis of sepsis. Lab Med 41:173–177CrossRefGoogle Scholar
  22. 22.
    Meisner M (2002) Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta 323:17–29PubMedCrossRefGoogle Scholar
  23. 23.
    Preas HL, Nylen ES, Snider RH et al (2001) Effects of anti-inflammatory agents on serum levels of calcitonin precursors during human experimental endotoxemia. J Infect Dis 184: 373–376PubMedCrossRefGoogle Scholar
  24. 24.
    Harbarth S, Holeckova K, Froidevaux C et al (2001) Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 164:396–402PubMedCrossRefGoogle Scholar
  25. 25.
    Aikawa N, Fujishima S, Endo S et al (2005) Multicenter prospective study of procalcitonin as an indicator of sepsis. J Infect Chemother 11:152–159PubMedCrossRefGoogle Scholar
  26. 26.
    Bassim CW, Redman RS, DeNucci DJ et al (2008) Salivary procalcitonin and periodontitis in diabetes. J Dent Res 87:630–634PubMedCrossRefGoogle Scholar
  27. 27.
    Forsberg JA, Elster EA, Andersen RC et al (2008) Correlation of procalcitonin and cytokine expression with dehiscence of wartime extremity wounds. J Bone Joint Surg Am 90: 580–588PubMedCrossRefGoogle Scholar
  28. 28.
    Jereb M, Muzlovic I, Hojker S, Strle F (2001) Predictive value of serum and cerebrospinal fluid procalcitonin levels for the diagnosis of bacterial meningitis. Infection 29:209–212PubMedCrossRefGoogle Scholar
  29. 29.
    Linssen CF, Bekers O, Drent M, Jacobs JA (2008) C-reactive protein and procalcitonin concentrations in bronchoalveolar lavage fluid as a predictor of ventilator-associated pneumonia. Ann Clin Biochem 45:293–298PubMedCrossRefGoogle Scholar
  30. 30.
    Wacker C, Prkno A, Brunkhorst FM, Schlattmann P (2013) Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 13: 426–435PubMedCrossRefGoogle Scholar
  31. 31.
    Daniels JM, Schoorl M, Snijders D et al (2010) Procalcitonin vs. C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest 138: 1108–1115PubMedCrossRefGoogle Scholar
  32. 32.
    Gaini S, Koldkjaer OG, Pedersen C, Pedersen SS (2006) Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit Care 10:R53PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Ugarte H, Silva E, Mercan D et al (1999) Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 27: 498–504PubMedCrossRefGoogle Scholar
  34. 34.
    Luzzani A, Polati E, Dorizzi R et al (2003) Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med 31: 1737–1741PubMedCrossRefGoogle Scholar
  35. 35.
    Uzzan B, Cohen R, Nicolas P et al (2006) Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 34:1996–2003PubMedCrossRefGoogle Scholar
  36. 36.
    Simon L, Gauvin F, Amre DK et al (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39:206–217PubMedCrossRefGoogle Scholar
  37. 37.
    Castelli GP, Pognani C, Cita M, Paladini R (2009) Procalcitonin as a prognostic and diagnostic tool for septic complications after major trauma. Crit Care Med 37:1845–1849PubMedCrossRefGoogle Scholar
  38. 38.
    Brodska H, Malickova K, Adamkova V et al (2013) Significantly higher procalcitonin levels could differentiate Gram-negative sepsis from Gram-positive and fungal sepsis. Clin Exp Med 13:165–170PubMedCrossRefGoogle Scholar
  39. 39.
    Charles PE, Ladoire S, Aho S et al (2008) Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either Gram negative or Gram positive bacteria. BMC Infect Dis 8:38PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Charles PE, Kus E, Aho S et al (2009) Serum procalcitonin for the early recognition of nosocomial infection in the critically ill patients: a preliminary report. BMC Infect Dis 9:49PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Theodorou VP, Papaioannou VE, Tripsianis GA et al (2012) Procalcitonin and procalcitonin kinetics for diagnosis and prognosis of intravascular catheter-related bloodstream infections in selected critically ill patients: a prospective observational study. BMC Infect Dis 12:247PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Sponholz C, Sakr Y, Reinhart K, Brunkhorst F (2006) Diagnostic value and prognostic implications of serum procalcitonin after cardiac surgery: a systematic review of the literature. Crit Care 10:R145PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Schuetz P, Affolter B, Hunziker S et al (2010) Serum procalcitonin, C-reactive protein and white blood cell levels following hypothermia after cardiac arrest: a retrospective cohort study. Eur J Clin Invest 40:376–381PubMedCrossRefGoogle Scholar
  44. 44.
    Giovanella L, Verburg FA, Imperiali M et al (2013) Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules. Clin Chem Lab Med 51:1477–1481PubMedGoogle Scholar
  45. 45.
    Brodska H, Drabek T, Malickova K et al (2009) Marked increase of procalcitonin after the administration of anti-thymocyte globulin in patients before hematopoietic stem cell transplantation does not indicate sepsis: a prospective study. Crit Care 13:R37PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    O’Grady NP, Barie PS, Bartlett JG et al (2008) Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med 36:1330–1349PubMedCrossRefGoogle Scholar
  47. 47.
    Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock—2012. Crit Care Med 41: 580–637PubMedCrossRefGoogle Scholar
  48. 48.
    Giamarellos-Bourboulis EJ, Tsangaris I, Kanni T et al (2011) Procalcitonin as an early indicator of outcome in sepsis: a prospective observational study. J Hosp Infect 77:58–63PubMedCrossRefGoogle Scholar
  49. 49.
    Bloos F, Marshall JC, Dellinger RP et al (2011) Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study. Crit Care 15:R88PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Karlsson S, Heikkinen M, Pettila V et al (2010) Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care 14:R205PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Schuetz P, Maurer P, Punjabi V et al (2013) Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients. Crit Care 17:R115PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Georgopoulou AP, Savva A, Giamarellos-Bourboulis EJ et al (2011) Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. J Crit Care 26:331–337PubMedCrossRefGoogle Scholar
  53. 53.
    Jensen JU, Heslet L, Jensen TH et al (2006) Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 34:2596–2602PubMedCrossRefGoogle Scholar
  54. 54.
    Charles PE, Tinel C, Barbar S et al (2009) Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome. Crit Care 13:R38PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Christ-Crain M, Jaccard-Stolz D, Bingisser R et al (2004) Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363:600–607PubMedCrossRefGoogle Scholar
  56. 56.
    Christ-Crain M, Stolz D, Bingisser R et al (2006) Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 174:84–93PubMedCrossRefGoogle Scholar
  57. 57.
    Stolz D, Christ-Crain M, Bingisser R et al (2007) Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 131:9–19PubMedCrossRefGoogle Scholar
  58. 58.
    Schuetz P, Christ-Crain M, Thomann R et al (2009) Effect of procalcitonin-based guidelines vs. standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 302: 1059–1066PubMedCrossRefGoogle Scholar
  59. 59.
    Kristoffersen KB, Sogaard OS, Wejse C et al (2009) Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission: a randomized trial. Clin Microbiol Infect 15:481–487PubMedCrossRefGoogle Scholar
  60. 60.
    Bouadma L, Luyt CE, Tubach F et al (2010) Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375:463–474PubMedCrossRefGoogle Scholar
  61. 61.
    Stolz D, Smyrnios N, Eggimann P et al (2009) Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 34:1364–1375PubMedCrossRefGoogle Scholar
  62. 62.
    Qu R, Ji Y, Ling Y et al (2012) Procalcitonin is a good tool to guide duration of antibiotic therapy in patients with severe acute pancreatitis. A randomized prospective single-center controlled trial. Saudi Med J 33:382–387PubMedGoogle Scholar
  63. 63.
    Nobre V, Harbarth S, Graf JD et al (2008) Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 177: 498–505PubMedCrossRefGoogle Scholar
  64. 64.
    Schroeder S, Hochreiter M, Koehler T et al (2009) Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 394:221–226PubMedCrossRefGoogle Scholar
  65. 65.
    Hochreiter M, Kohler T, Schweiger AM et al (2009) Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 13:R83PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Stocker M, Fontana M, El HS et al (2010) Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial. Neonatology 97:165–174PubMedCrossRefGoogle Scholar
  67. 67.
    Layios N, Lambermont B, Canivet JL et al (2012) Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Crit Care Med 40:2304–2309PubMedCrossRefGoogle Scholar
  68. 68.
    Jensen JU, Hein L, Lundgren B et al (2011) Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 39: 2048–2058PubMedCrossRefGoogle Scholar
  69. 69.
    Schuetz P, Briel M, Christ-Crain M et al (2012) Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 55:651–662PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Kopterides P, Siempos II, Tsangaris I et al (2010) Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med 38: 2229–2241PubMedCrossRefGoogle Scholar
  71. 71.
    Matthaiou DK, Ntani G, Kontogiorgi M et al (2012) An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med 38:940–949PubMedCrossRefGoogle Scholar
  72. 72.
    Heyland DK, Johnson AP, Reynolds SC, Muscedere J (2011) Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 39:1792–1799PubMedCrossRefGoogle Scholar
  73. 73.
    Oliveira CF, Botoni FA, Oliveira CR et al (2013) Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Crit Care Med 41:2336–2343PubMedCrossRefGoogle Scholar
  74. 74.
    Clec’h C, Fosse JP, Karoubi P et al (2006) Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit Care Med 34:102–107PubMedCrossRefGoogle Scholar
  75. 75.
    Kofoed K, Andersen O, Kronborg G et al (2007) Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 11:R38PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Ruiz-Alvarez MJ, Garcia-Valdecasas S, De Pablo R et al (2009) Diagnostic efficacy and prognostic value of serum procalcitonin concentration in patients with suspected sepsis. J Intensive Care Med 24:63–71PubMedCrossRefGoogle Scholar
  77. 77.
    Tsangaris I, Plachouras D, Kavatha D et al (2009) Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay. BMC Infect Dis 9:213PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Hsu KH, Chan MC, Wang JM et al (2011) Comparison of Fcgamma receptor expression on neutrophils with procalcitonin for the diagnosis of sepsis in critically ill patients. Respirology 16:152–160PubMedCrossRefGoogle Scholar
  79. 79.
    Meynaar IA, Droog W, Batstra M et al (2011) In critically ill patients, serum procalcitonin is more useful in differentiating between sepsis and SIRS than CRP, Il-6, or LBP. Crit Care Res Pract 2011:594645PubMedPubMedCentralGoogle Scholar
  80. 80.
    Bele N, Darmon M, Coquet I et al (2011) Diagnostic accuracy of procalcitonin in critically ill immunocompromised patients. BMC Infect Dis 11:224PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Hoeboer SH, Alberts E, van den Hul I et al (2012) Old and new biomarkers for predicting high and low risk microbial infection in critically ill patients with new onset fever: a case for procalcitonin. J Infect 64:484–493PubMedCrossRefGoogle Scholar
  82. 82.
    Sakran JV, Michetti CP, Sheridan MJ, et al (2012) The utility of procalcitonin in critically ill trauma patients. J Trauma Acute Care Surg 73:413–418PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Jean-Louis Vincent
    • 1
    Email author
  • Marc Van Nuffelen
    • 2
  • Christophe Lelubre
    • 2
  1. 1.Department of Intensive CareErasme Hospital, Université Libre de BruxellesBrusselsBelgium
  2. 2.Department of Intensive CareErasme Hospital, Université Libre de BruxellesBrusselsBelgium

Personalised recommendations